NCT02923180: Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 33 taking part
- Started
- 14 Feb 2017
- Primary completion
- 11 Aug 2020
- Arms
- Enoblituzumab
- Results
- Posted on the registry
- 4 Oct 2016: Trial registered
- 14 Feb 2017: Trial started
- 24 Aug 2021: Trial results posted